Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 8/2017

23.05.2017 | 2016 SSAT Plenary Presentation

Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival

verfasst von: Matteo Donadon, Kelly Hudspeth, Matteo Cimino, Luca Di Tommaso, Max Preti, Paolo Tentorio, Massimo Roncalli, Domenico Mavilio, Guido Torzilli

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Cancer heterogeneity and degree of intra-tumoral immune cells represent variables affecting overall survival (OS). The present study investigated the impact of natural killer (NK) and T cells infiltrating colorectal liver metastases (CLM) in patients undergoing hepatectomy after neoadjuvant chemotherapy.

Methods

The frequencies of intra-tumoral, marginal, and peritumoral CD3+ T and NKp46+ NK cells were determined for 121 patients. OS was assessed in relation to prognostic factors.

Results

At univariate analysis, several variables, including T and N of the primary tumor, metachronous CLM, radiological response, and higher density of intra-tumoral CD3+ T cell (>1%/mm2) and of NKp46+ NK cells (>1 cell/mm2), were associated with OS. Only increased frequencies of intra-tumoral CD3+ T cells (p = 0.005) and NKp46+ NK cells (p = 0.004) correlated with OS at multivariate analysis. The logistic regression revealed that metachronous CLM (OR = 2.781; p = 0.002), the use of an epidermal growth factor receptor inhibitor (OR = 3.891; p = 0.001), and radiological response (OR = 3.219; p = 0.001) were associated with higher infiltration of these cells.

Conclusions

High frequencies of NK and T cells in response to chemotherapy predict OS in CLM patients. These findings provide important insights that can help physicians to choose the best treatment option and adopt more predictive follow-up strategies for patients with CLM.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Cucchetti A, Ferrero A, Cescon M, Donadon M, Russolillo N, Ercolani G et al. Cure model survival analysis after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2015;22:1908–14.CrossRefPubMed Cucchetti A, Ferrero A, Cescon M, Donadon M, Russolillo N, Ercolani G et al. Cure model survival analysis after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2015;22:1908–14.CrossRefPubMed
2.
Zurück zum Zitat Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371(9617):1007–16.CrossRefPubMedPubMedCentral Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371(9617):1007–16.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012;17:1225–39.CrossRefPubMedPubMedCentral Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012;17:1225–39.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 2014;25:1018–25.CrossRefPubMed Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 2014;25:1018–25.CrossRefPubMed
5.
Zurück zum Zitat Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677–83.CrossRefPubMedPubMedCentral Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677–83.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309–18.CrossRefPubMedPubMedCentral Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309–18.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77:1254–62.CrossRefPubMed Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77:1254–62.CrossRefPubMed
8.
Zurück zum Zitat Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008;247:125–35.CrossRefPubMed Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008;247:125–35.CrossRefPubMed
9.
Zurück zum Zitat Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012;4:283–301.PubMedPubMedCentral Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012;4:283–301.PubMedPubMedCentral
11.
Zurück zum Zitat Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009;10:877–84.CrossRefPubMed Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol 2009;10:877–84.CrossRefPubMed
12.
Zurück zum Zitat Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313(5795):1960–4.CrossRefPubMed Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313(5795):1960–4.CrossRefPubMed
13.
Zurück zum Zitat Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997;182:318–24.CrossRefPubMed Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997;182:318–24.CrossRefPubMed
14.
Zurück zum Zitat Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491–4.PubMed Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491–4.PubMed
15.
Zurück zum Zitat Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M et al. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 2009;16:2524–30.CrossRefPubMed Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M et al. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 2009;16:2524–30.CrossRefPubMed
16.
Zurück zum Zitat Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC et al. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 2013;20:946–55.CrossRefPubMed Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC et al. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 2013;20:946–55.CrossRefPubMed
17.
Zurück zum Zitat Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186–92.CrossRefPubMed Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186–92.CrossRefPubMed
18.
Zurück zum Zitat Doherty DG, Norris S, Madrigal-Estebas L, McEntee G, Traynor O, Hegarty JE et al. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 1999;163:2314–21.PubMed Doherty DG, Norris S, Madrigal-Estebas L, McEntee G, Traynor O, Hegarty JE et al. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 1999;163:2314–21.PubMed
19.
Zurück zum Zitat Hata K, Van Thiel DH, Herberman RB, Whiteside TL. Natural killer activity of human liver-derived lymphocytes in various liver diseases. Hepatology 1991;14:495–503.CrossRefPubMed Hata K, Van Thiel DH, Herberman RB, Whiteside TL. Natural killer activity of human liver-derived lymphocytes in various liver diseases. Hepatology 1991;14:495–503.CrossRefPubMed
20.
Zurück zum Zitat Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M et al. Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J Autoimmun 2016;66:40–50.CrossRefPubMed Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M et al. Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J Autoimmun 2016;66:40–50.CrossRefPubMed
21.
Zurück zum Zitat Lee WS, Kang M, Baek JH, Lee JI, Ha SY. Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. Ann Surg Oncol 2013;20:697–702.CrossRefPubMed Lee WS, Kang M, Baek JH, Lee JI, Ha SY. Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. Ann Surg Oncol 2013;20:697–702.CrossRefPubMed
22.
Zurück zum Zitat Belghiti J, Clavien P, Gadzijev E, Garden JO, Lau W, Makuuchi M et al. The Brisbane 2000 terminology of liver anatomy and resections. International Hepato Pancreato Biliary World Congress - HBP 2000;2:333–9. Belghiti J, Clavien P, Gadzijev E, Garden JO, Lau W, Makuuchi M et al. The Brisbane 2000 terminology of liver anatomy and resections. International Hepato Pancreato Biliary World Congress - HBP 2000;2:333–9.
23.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications—A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery 2004;240:205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications—A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery 2004;240:205–13.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Jnci-J Natl Cancer I 2014;106(6) dju124. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Jnci-J Natl Cancer I 2014;106(6) dju124.
25.
Zurück zum Zitat Torzilli G. An Atlas (First Edition). Springer, Milan. 2014:280. Torzilli G. An Atlas (First Edition). Springer, Milan. 2014:280.
26.
27.
Zurück zum Zitat Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Annals of Oncology 2007;18:299–304.CrossRefPubMed Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Annals of Oncology 2007;18:299–304.CrossRefPubMed
28.
Zurück zum Zitat Tanis E, Julie C, Emile JF, Mauer M, Nordlinger B, Aust D et al. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. Eur J Cancer 2015;51:2708–17.CrossRefPubMed Tanis E, Julie C, Emile JF, Mauer M, Nordlinger B, Aust D et al. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. Eur J Cancer 2015;51:2708–17.CrossRefPubMed
29.
Zurück zum Zitat Marquardt N, Beziat V, Nystrom S, Hengst J, Ivarsson MA, Kekalainen E et al. Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells. J Immunol 2015;194:2467–71.CrossRefPubMed Marquardt N, Beziat V, Nystrom S, Hengst J, Ivarsson MA, Kekalainen E et al. Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells. J Immunol 2015;194:2467–71.CrossRefPubMed
30.
Zurück zum Zitat Hoffmann TK, Schirlau K, Sonkoly E, Brandau S, Lang S, Pivarcsi A et al. A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int J Cancer 2009;124:2589–96.CrossRefPubMed Hoffmann TK, Schirlau K, Sonkoly E, Brandau S, Lang S, Pivarcsi A et al. A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int J Cancer 2009;124:2589–96.CrossRefPubMed
31.
Zurück zum Zitat Ito Y, Correll K, Zemans RL, Leslie CC, Murphy RC, Mason RJ. Influenza induces IL-8 and GM-CSF secretion by human alveolar epithelial cells through HGF/c-Met and TGF-alpha/EGFR signaling. Am J Physiol Lung Cell Mol Physiol 2015;308:L1178–88.CrossRefPubMedPubMedCentral Ito Y, Correll K, Zemans RL, Leslie CC, Murphy RC, Mason RJ. Influenza induces IL-8 and GM-CSF secretion by human alveolar epithelial cells through HGF/c-Met and TGF-alpha/EGFR signaling. Am J Physiol Lung Cell Mol Physiol 2015;308:L1178–88.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–85.CrossRefPubMed Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–85.CrossRefPubMed
33.
Zurück zum Zitat Bier H, Hoffmann T, Haas I, van Lierop A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998;46(3):167–73.CrossRefPubMed Bier H, Hoffmann T, Haas I, van Lierop A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998;46(3):167–73.CrossRefPubMed
34.
Zurück zum Zitat Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007;13(21):6419–28.CrossRefPubMed Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007;13(21):6419–28.CrossRefPubMed
35.
Zurück zum Zitat Arjaans M, Schroder CP, Oosting SF, Dafni U, Kleibeuker JE, de Vries EG. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget 2016; 19:21247–58. Arjaans M, Schroder CP, Oosting SF, Dafni U, Kleibeuker JE, de Vries EG. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget 2016; 19:21247–58.
36.
Zurück zum Zitat Primrose J, Falk S, Finch-Jones M, Valle J, O’Reilly D, Siriwardena A et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014;15:601–11.CrossRefPubMed Primrose J, Falk S, Finch-Jones M, Valle J, O’Reilly D, Siriwardena A et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014;15:601–11.CrossRefPubMed
37.
Zurück zum Zitat Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45.CrossRefPubMed Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45.CrossRefPubMed
38.
Zurück zum Zitat Garrido G, Lorenzano P, Sanchez B, Beausoleil I, Alonso DF, Perez R et al. T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. Cancer Immunol Immun. 2007;56:1701–10.CrossRef Garrido G, Lorenzano P, Sanchez B, Beausoleil I, Alonso DF, Perez R et al. T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. Cancer Immunol Immun. 2007;56:1701–10.CrossRef
Metadaten
Titel
Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival
verfasst von
Matteo Donadon
Kelly Hudspeth
Matteo Cimino
Luca Di Tommaso
Max Preti
Paolo Tentorio
Massimo Roncalli
Domenico Mavilio
Guido Torzilli
Publikationsdatum
23.05.2017
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 8/2017
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-017-3446-6

Weitere Artikel der Ausgabe 8/2017

Journal of Gastrointestinal Surgery 8/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.